ABBV Stock: Unusual Options Activity Flags Bullish Bet as AbbVie Trades Near 52-Week Highs
By TrendSpider Editor
A single unusual call contract totaling $1,098,000 in premium has surfaced in AbbVie Inc. options trading, drawing attention to the large-cap pharmaceutical name. AbbVie shares are currently trading at $226.00, down 0.74% on the session, but remain well above the 52-week low of $164.39. With the 52-
ABBV Stock: Unusual Options Activity Flags Bullish Bet as AbbVie Trades Near 52-Week Highs
A single unusual call contract totaling $1,098,000 in premium has surfaced in AbbVie Inc. options trading, drawing attention to the large-cap pharmaceutical name. AbbVie shares are currently trading at $226.00, down 0.74% on the session, but remain well above the 52-week low of $164.39. With the 52-week high sitting at $244.81, the stock has substantial room to extend its longer-term advance if bullish momentum returns.
Key Drivers of the ABBV Stock Move
- Main Catalyst: One unusual call option contract was flagged today on AbbVie, carrying a total premium of $1,098,000. The contract is a $220 strike call expiring June 18, 2026, with a size of 600 contracts and an open interest utilization of 41%. The contract is currently in the money with shares trading at $226.00.
- Bull Case: The fact that this call is already in the money at the $220 strike, with the stock at $226.00, suggests the buyer is positioning for continued upside through June 2026. The $1,098,000 premium commitment signals conviction, and the stock remains nearly 38% above its 52-week low of $164.39, reflecting a strong underlying trend.
- Bear Case: AbbVie shares are down 0.74% on the session and are trading roughly $18.81 below the 52-week high of $244.81. If the stock fails to maintain momentum through the June 2026 expiration, the in-the-money call buyer risks losing a significant portion of the $1,098,000 premium deployed. The single-contract nature of the unusual activity, with no put activity flagged, could also reflect a hedged institutional position rather than a purely directional bet.
The options activity arrives at an interesting moment for AbbVie as the company continues to navigate its post-Humira transition, leaning heavily on growth assets including Skyrizi and Rinvoq to offset biosimilar pressure. The June 2026 expiration window gives the position several months to play out through what will likely be additional earnings reports and pipeline updates. With the stock holding above the $220 strike and trading in the upper half of its 52-week range between $164.39 and $244.81, the near-term technical backdrop broadly supports the bullish options positioning, though any macro or pipeline-related headwinds could pressure the trade.
ABBV Unusual Options Activity
One unusual options contract was flagged in AbbVie today:
- Type: Call | Strike: $220 | Expiry: June 18, 2026 | Volume (Size): 600 contracts | Open Interest Utilization: 41% | Status: In the Money
Total premium associated with this contract is $1,098,000. No put contracts were flagged in today's unusual activity scan, leaving the options flow skewed entirely bullish on a net basis.
ABBV Seasonality
March has historically been an active period for pharmaceutical names as investors position ahead of mid-year catalysts, including medical conferences and pipeline readouts that often occur in the spring and early summer months. The June 18, 2026 expiration on the flagged call aligns with this window, suggesting the buyer may be targeting a specific near-term event or catalyst expected before that date.
ABBV Relative Performance
AbbVie shares are trading at $226.00, down 0.74% on the session. Within the context of its own 52-week range of $164.39 to $244.81, the stock is currently positioned in the upper portion of that range, approximately 75% of the way from the 52-week low to the 52-week high. This relative positioning suggests AbbVie has broadly outperformed through the past year and continues to hold its longer-term gains even as it experiences a modest pullback in today's session.